Nifty Smallcap 250
Index Fund
An Open-ended Equity Scheme replicating Nifty Next 50 Index
Data as on 31st October, 2024
| Investment Objective : The investment objective of the scheme is to provide returns before expenses that closely correspond to the total returns of the Nifty Smallcap 250 Index subject to tracking errors. However, there is no assurance that the investment objective of the Scheme will be realized and the Scheme does not assure or guarantee any returns. |
|
| Inception Date | 30-Nov-2022 |
| Benchmark | Nifty Smallcap 250 TRI |
| Fund Managers Details | Mr. Bhavesh Jain Experience 16 years Managing Since 30-Nov-2022 |
| Additional investment amount | Minimum of Rs. 100/- and multiples of Re. 1/- thereafter |
| Minimum Investment Amount | Minimum of Rs. 100/- and multiples of Re. 1/- thereafter. |
| Exit Load | NIL |
| Total Expense Ratios~: | Regular 0.84% Direct 0.14% |
| Month End AUM |
Rs. 91.28 Crore
|
| Monthly Average AUM |
Rs. 88.62 Crore
|
Regular Plan - Growth |
18.1727 |
Regular Plan - IDCW |
18.1726 |
|
Direct Plan - Growth
|
18.4168
|
|
Direct Plan - IDCW
|
18.4173
|
| (as on October 31, 2024) |
|
Name of Instrument
|
Industry
|
% to Net Assets
|
| Multi Commodity Exchange Of India Ltd. | Financial Services | 1.73% |
| Central Depository Services (I) Ltd. | Financial Services | 1.44% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 1.33% |
| Crompton Greaves Cons Electrical Ltd. | Consumer Durables | 1.31% |
| Blue Star Ltd. | Consumer Durables | 1.26% |
| Computer Age Management Services Ltd. | Financial Services | 1.11% |
| National Aluminium Company Ltd. | Metals & Mining | 1.06% |
| Laurus Labs Ltd. | Healthcare | 1.01% |
| Radico Khaitan Ltd. | Fast Moving Consumer Goods | 0.97% |
| Karur Vysya Bank Ltd. | Financial Services | 0.93% |
| Angel One Ltd. | Financial Services | 0.92% |
| Amara Raja Energy & Mobility Ltd. | Automobile & Auto Components | 0.89% |
| Apar Industries Ltd. | Capital Goods | 0.89% |
| Cholamandalam Financial Holdings Ltd. | Financial Services | 0.88% |
| Suven Pharmaceuticals Ltd. | Healthcare | 0.87% |
| Piramal Pharma Ltd. | Healthcare | 0.86% |
| Brigade Enterprises Ltd. | Realty | 0.85% |
| Cyient Ltd. | Information Technology | 0.81% |
| 360 One Wam Ltd. | Financial Services | 0.79% |
| Kaynes Technology India Ltd. | Capital Goods | 0.77% |
| Inox Wind Ltd. | Capital Goods | 0.76% |
| NCC Ltd. | Construction | 0.76% |
| Elgi Equipments Ltd. | Capital Goods | 0.75% |
| Aditya Birla Real Estate Ltd. | Forest Materials | 0.74% |
| JB Chemicals & Pharmaceuticals Ltd. | Healthcare | 0.73% |
| Motilal Oswal Financial Services Ltd. | Financial Services | 0.71% |
| Himadri Speciality Chemical Ltd. | Chemicals | 0.71% |
| Krishna Inst of Medical Sciences Ltd. | Healthcare | 0.70% |
| Indian Energy Exchange Ltd. | Financial Services | 0.70% |
| Kalpataru Projects International Ltd. | Construction | 0.70% |
| Other | 72.06% |
|
Period
|
Scheme - Edelweiss Nifty Smallcap
250 Index Fund |
Benchmark (Nifty Smallcap 250 TR Index) |
Additional Benchmark (Nifty 50 TR Index) |
|||
|
Returns |
Value of Rs. 10000 Invested |
Returns |
Value of Rs. 10000 Invested |
Returns |
Value of Rs. 10000 Invested |
|
|
1 Year |
46.73% |
14,689 |
48.41% |
14,857 |
28.30% |
12,839 |
|
Since Inception - Regular Plan |
36.48% |
18,173 |
38.22% |
18,620 |
15.50% |
13,188 |
Past performance may or may not be sustained in future and
should not be used as a basis for comparison with other investments.
Notes:
1. The scheme is currently managed by Bhavesh Jain (managing this fund from November 30, 2022 ). Please Click here
for name of the
other schemes currently managed by the Fund Managers and relevant scheme for performance.
|
Total stocks
in portfolio
|
250
|
| Top 10 stocks | 12.15% |
| Portfolio Turnover Ratio^ |
0.47
|
|
Tracking Error (Regular)
|
0.24%
|
| Tracking error is annualised and is calculated based on data since inception. | |
Disclaimer of NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Scheme Information Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Scheme Information Document. The investors are advised to refer to the Scheme Information Document for the full text of the 'Disclaimer Clause of NSE'.
This Product is suitable for investors who are seeking*:
- Long term capital appreciation
- Passive Investment in equity and equity related securities replicating the composition of Nifty Small Cap 250 Index, subject to tracking errors
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.
Investors understand that their principal will be at Very High Risk
Benchmark Riskometer: Nifty Next 50 TRI
Investors understand that their principal will be at Very High Risk